VolitionRx Limited hosted a symposium at ESICM Lives 2024 in Barcelona on October 7, 2024, where experts presented findings from large, independent studies regarding the potential of using Nu.Q® NETs to determine a 'treatable trait' to enhance sepsis management. The session, titled 'NETs: Casting a new light on sepsis management,' was chaired by Professor Djillali Annane.
Professor Annane, a world-renowned expert in sepsis, stated that it is becoming increasingly evident that Nu.Q® NETs could play an integral role in sepsis management. Elevated levels of H3.1 nucleosomes, a surrogate marker for Neutrophil Extracellular Traps (NETs), are both a marker of severity and a cause of consequence in sepsis.
The symposium explored the role of H3.1 nucleosomes in NETosis, the clinical utility of H3.1 in recent large-scale studies, and how the Nu.Q® NETs biomarker has the potential to predict organ failure. Professor Annane believes Nu.Q® NETs, as a diagnostic tool, has the potential to bring about a paradigm shift in sepsis management, helping to detect, treat, and monitor sepsis earlier and save lives.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.